SCHEMBL21583996

SCHEMBL21583996

Brc1ccc2c(c1)OCCCn1cc(I)nc1-2

nearest known ligand 0.39

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 4/20 0.39
PIK3CA P42336 12/20 0.39
PIK3CG P48736 5/20 0.39
PIK3CD O00329 5/20 0.39
PIK3CB P42338 4/20 0.39
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1485055 0.93 PIK3CA (0.42) PIK3CAPIK3CGPIK3CDPIK3CB
SCHEMBL1485090 0.83 PIK3CA (0.54) MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB
SCHEMBL19594359 0.78 PIK3CA (0.43) PIK3CAPIK3CGPIK3CDPIK3CB
SCHEMBL21583987 0.78 PIK3CA (0.43) MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB
SCHEMBL21583986 0.77 GABRG2 (0.40) MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB
SCHEMBL1485608 0.77 MAP3K5 (0.39) MAP3K5PIK3CAPIK3CGPIK3CDPIK3CB
SCHEMBL21583989 0.77 PBRM1 (0.37) MAP3K5PIK3CA
SCHEMBL29792860 0.77 PBRM1 (0.37) MAP3K5PIK3CA
SCHEMBL12539133 0.76 PIK3CD (0.40) PIK3CAPIK3CD
SCHEMBL1485023 0.74 PIK3CA (0.40) PIK3CAPIK3CGPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630561-B2 Tricyclic derivatives inhibitor, preparation method, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2026-05-19 US disclosed
EP-3805231-B1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) 2024-10-16 EP disclosed
CN-114835729-B Inhibitor containing tricyclic derivatives, preparation method and application thereof 江苏豪森药业集团有限公司 2024-05-31 CN disclosed
CN-114835729-A Tricyclic derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2022-08-02 CN disclosed
CN-110785423-B Tricyclic derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2022-07-26 CN disclosed
US-20210221822-A1 TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2021-07-22 US disclosed
EP-3805231-A1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2021-04-14 EP disclosed
EP-3805231-A1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2021-04-14 EP disclosed
WO-2019228341-A1 INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 江苏豪森药业集团有限公司 (CN) 2019-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221822-A1 TRICYCLIC DERIVATIVES INHIBITOR, PREPARATION METHOD, AND APPLICATIONS THEREOF PIK3CA, PIK3CD, PIK3CB MAP3K5 94/4885PIK3CA 1/4885PIK3CG 4/4885
US-12630561-B2 Tricyclic derivatives inhibitor, preparation method, and applications thereof PIK3CA, PIK3R1, PIK3CD MAP3K5 527/4885PIK3CA 1/4885PIK3CG 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.